News

Medtronic Has Launched Adaptive Deep Brain Stimulation for Parkinson's in India — Your Brain Tells the Device When to Adjust. It Listens.

"Adaptive DBS represents the next major evolution from conventional, continuous DBS therapy. By actively monitoring the brain's unique electrical signals, the system responds instantaneously, delivering the precise amount of stimulation exactly when it is needed."

By Mustafa Shariff, Editor in Chief · April 25,2026 · 5 min read

Summary

• Medtronic Adaptive DBS India Launch: How Real-Time Brain Sensing Is Transforming Parkinson's Treatment
• Medtronic has launched its Adaptive Deep Brain Stimulation (aDBS) system in India. Here is the full story of the technology, India's Parkinson's burden, and why this launch matters for Indian neurology.

Medtronic, the global healthcare technology leader, has formally launched its Adaptive Deep Brain Stimulation (aDBS) system in India — a next-generation neurostimulation therapy for Parkinson's disease that represents a meaningful advance over conventional DBS in how it responds to individual patient symptoms. The launch formalises a technology that has already been clinically activated in India: Apollo Hospitals Chennai performed India's first aDBS clinical activation on March 2, 2026, under the leadership of Dr Vijayashankar Paramanandam, Senior Consultant Neurologist and Movement Disorders and DBS Specialist.

Parkinson's disease is India's most significant movement disorder. A recent British Medical Journal study estimates that India will have approximately 2.8 million patients living with Parkinson's by 2050 — second only to China and accounting for nearly one-tenth of global cases. India's Parkinson's population is projected to grow 160-180% over current levels, driven by demographic ageing, better diagnosis, and growing physician awareness. The prevalence of Parkinson's in India today is roughly 10% of global burden — a considerable and growing public health concern that makes every advance in Parkinson's treatment directly relevant to millions of Indian patients.

How Conventional DBS Works — and Its Limitations

Deep Brain Stimulation has been one of the most transformative advances in Parkinson's treatment of the past three decades. The procedure involves implanting electrodes in specific areas of the brain — typically the subthalamic nucleus or globus pallidus — that are connected to a pulse generator implanted in the chest. The device delivers continuous electrical stimulation to these brain regions, modulating the abnormal neural circuits that cause Parkinson's motor symptoms: tremor, rigidity, bradykinesia (slowness of movement), and gait disturbances. For appropriately selected patients, conventional DBS produces dramatic symptom improvement.

The limitation of conventional DBS is that it is fixed and continuous: it delivers the same level of stimulation regardless of what the patient is doing, how their symptoms are fluctuating, or what their brain signals indicate at any given moment. Parkinson's symptoms fluctuate significantly throughout the day — affected by medication cycles, physical activity, sleep, and stress. Fixed stimulation calibrated for one symptom state may be excessive or insufficient at other times, leading to sub-optimal symptom control across the full spectrum of daily life.

What Adaptive DBS Does Differently

Medtronic's Adaptive DBS system introduces a sensing layer that changes the fundamental operating principle of neurostimulation. The aDBS system continuously monitors the patient's own brain electrical activity — specifically, the local field potentials generated by the neural circuits being stimulated. These brain signals encode information about the current state of the motor system: whether it is in an over-active state generating tremor and rigidity, or a normal state that requires less therapeutic intervention.

By reading these brain signals in real time and using them as a feedback signal to adjust stimulation parameters — increasing stimulation when brain signals indicate elevated motor circuit activity and reducing it when signals indicate a more normal state — the aDBS system creates a closed-loop therapy that responds to the patient's actual neurological state rather than applying a predetermined fixed programme. The result is stimulation that is more precisely calibrated to need, with the potential for better symptom control across a broader range of daily activities and reduced side effects from over-stimulation.

Why India Needs Advanced Parkinson's Treatment

India's Parkinson's care landscape faces two specific challenges beyond the disease burden itself. The first is specialist access: trained movement disorder neurologists and neurosurgeons with DBS expertise are concentrated in a small number of major academic and private medical centres — Apollo, AIIMS, NIMHANS, Fortis, and a handful of others. Most Indian Parkinson's patients are managed by general neurologists who may have limited experience with advanced neuromodulation therapies. The aDBS launch by Medtronic, combined with training programmes at centres like Apollo Chennai, creates the specialist capability pipeline that can eventually extend advanced DBS to a broader population of Indian Parkinson's patients.

The second challenge is medication management. India's Parkinson's patients depend heavily on oral levodopa therapy — the primary pharmacological treatment — which becomes progressively less effective and produces unpredictable 'on-off' motor fluctuations as the disease advances. DBS — and aDBS specifically — provides an alternative for patients whose medication therapy is no longer providing adequate control, extending the window of functional independence and quality of life.

BHC Perspective

At Bengaluru Health Community, the Medtronic aDBS India launch is a neurotechnology story with direct relevance to our ecosystem. Bengaluru's NIMHANS — the National Institute of Mental Health and Neuro Sciences — is India's premier neuroscience institution, with a Parkinson's and movement disorders programme that is among the most active in the country. The aDBS launch expands the clinical options available within Bengaluru's neurology ecosystem and creates commercial opportunities for health technology companies building monitoring, rehabilitation, and care management tools for Parkinson's patients.

Frequently Asked Questions

Q: What is Adaptive Deep Brain Stimulation (aDBS)?
A: Unlike conventional DBS which delivers fixed continuous stimulation, aDBS senses the patient's own brain electrical signals in real time and adjusts stimulation accordingly — creating a closed-loop therapy that responds to actual neurological state rather than a predetermined programme.

Q: Why is aDBS launched in India significant?
A: India carries approximately 10% of global Parkinson's burden with an estimated 2.8 million patients by 2050, projected to grow 160-180%. Apollo Hospitals Chennai performed India's first aDBS clinical activation on March 2, 2026. Medtronic's formal launch opens the therapy to India's broader neuromodulation-capable hospital centres.

Q: How does aDBS improve on conventional DBS?
A: Conventional DBS delivers the same stimulation regardless of symptom fluctuations. aDBS reads brain signals to adjust stimulation in real time — potentially producing better symptom control across daily activities, reducing over-stimulation side effects, and extending functional independence for Parkinson's patients.